Business Context and Reporting Period
This Form 8-K is a current report filed by Cerulean Pharma Inc. on October 8, 2014. The report discloses corporate governance changes effective October 3, 2014, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointment: Susan Kelley was appointed as a Class I director, effective immediately.
- Independence: The Board determined Dr. Kelley is "independent" under Nasdaq Stock Market rules.
Compensation and Governance Details
- Director Compensation: Dr. Kelley will receive standard non-employee director compensation.
- Stock Option Grant: A one-time nonqualified stock option to purchase 15,000 shares of common stock was granted.
- Option Terms: The exercise price is $4.74 per share (closing price on grant date). The option vests in equal annual installments over three years, contingent on continued service.
- Indemnification: An indemnification agreement was executed on October 6, 2014, covering expenses, judgments, fines, and settlements arising from her service as a director.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 15,000 share option grant on potential dilution.
- Confirm the vesting schedule and exercise price of the granted options against the company's 2014 Stock Incentive Plan.
- Review Dr. Kelley's prior roles at Bayer, Bristol-Myers Squibb, and the Multiple Myeloma Research Consortium for potential conflicts of interest or strategic alignment.
- Check the company's latest financial filings (10-K or 10-Q) for actual liquidity and cash position, as this 8-K does not contain financial data.